Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Acknowledgement to reviewers111
Survival following resection of 10,244 lung neuroendocrine tumours: a population study94
Refining long-term surveillance requirements in patients with differentiated thyroid cancer66
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression54
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms51
Defining aging-associated factors that increase susceptibility to prostate cancer48
Prognostic of recurrence and survival in poorly differentiated thyroid cancer47
Acknowledgement to reviewers47
Targeting growth hormone in cancer: future perspectives34
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients33
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas33
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing33
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs31
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications31
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study29
Update on the genetics of paragangliomas28
Metastatic Neuroendocrine Neoplasms to the Breast: A Systematic Review27
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells27
Peptide receptor radionuclide therapy in malignant insulinoma26
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells26
Radiation Reprograms Fibroblasts to Drive Prostate Cancer Therapy Resistance26
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation25
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas24
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts24
Impact of sex hormones on development and progression in NEN: a new therapeutic target?23
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet22
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells21
Metabolically active brown adipose tissue in PPGL: an observational cohort study20
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma18
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation18
Whole-exome sequencing of rectal neuroendocrine tumors17
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells17
Gender-affirming care and endocrine-related cancers16
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia16
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly15
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours15
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer15
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction15
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective14
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen14
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis14
Effect of TSH levels during active surveillance of PTMC according to age14
ThyroidPrint®: clinical utility for indeterminate thyroid cytology14
Immunotherapy for endocrine tumours: a clinician’s perspective14
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring14
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors13
From bench to bedside in the sella: translational developments in pituitary tumour genetics13
Steroid profile in patients with breast cancer and in mice treated with mifepristone13
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms13
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study13
Acknowledgement to reviewers12
Exploring stem cell biology in pituitary tumors and derived organoids12
Acknowledgement to reviewers12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis12
Inhibition of GATA2 in prostate cancer by a clinically available small molecule12
Ciliogenesis in Pancreatic Neuroendocrine Tumors: Insight into the Role of WDR6012
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma11
New therapeutic opportunities for women with low-grade serous ovarian cancer11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study11
Clinical features of plurihormonal pituitary adenoma subtypes11
Systems biology successes and areas for opportunity in prostate cancer11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice10
Genetic disorders and insulinoma/glucagonoma10
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-210
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland10
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer10
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies9
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers9
Non-pituitary GH regulation of the tissue microenvironment9
Beyond the three P’s: adrenal involvement in MEN19
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort9
Surrogate molecular classification of LAR breast cancer in routine workflow9
Genetic variants and down-regulation of CACNA1H in pheochromocytoma9
Deiodinases in thyroid tumorigenesis9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer9
In memoriam: Charis Eng MD PhD (1962–2024)9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L29
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane8
The science behind the relations among cancer, height, growth patterns, and growth hormone axis8
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma8
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer8
Precocious puberty due to intracranial germ cell tumors: a case–control study8
MicroRNAs as regulators of tumor metabolism8
0.10442996025085